Quoin Pharmaceuticals (QNRX) Stock: Buy, Sell, or Hold?
QNRX - Quoin Pharmaceuticals, Ltd. American Depositary Shares
$6.79
-0.11 (-1.59%)
▼
5d:
-13.72%
30d:
+15.28%
90d:
+44.47%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 05, 2026
Get Alerted When QNRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: QNRX is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: QNRX is down 13.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: QNRX is currently trading at $6.79, which is considered extended relative to its 30-day fair value range of $4.86 to $6.72.
Technical Outlook: Technically, QNRX is showing sideways momentum. Immediate support is located at $5.43, while resistance sits at $8.25.
Market Sentiment: QNRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.20 (+227.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, QNRX is showing sideways momentum. Immediate support is located at $5.43, while resistance sits at $8.25.
Market Sentiment: QNRX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $22.20 (+227.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$4.86 -
$6.72
Company Quality Score
33/100
(SELL)
Volume Confirmation
MODERATE
Confidence Score
21.1%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (0/100)
- BULLISH: Trading 227.0% below Wall St target ($22.20)
- WARNING: Composite score 33/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.86 -
$6.72
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.43
Resistance Level
$8.25
Current Trend
Sideways
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.13
Wall Street Target
$22.20
(+227.0%)
Share & Embed Analysis
Last updated: September 13, 2026 10:07 AM ET
Data refreshes hourly during market hours. Next update: 11:07 AM
Data refreshes hourly during market hours. Next update: 11:07 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QNRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$24 | 32 SELL |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$48 | 44 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1180 | 43 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 34 SELL |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$137 | 47 HOLD |
